Research & Evidence Assets
Dated, source-linked evidence maps and regulatory or product datasets built from public records—never invented clinical or laboratory data.
What matters first
Original editorial analysis can organize public evidence, surface reporting gaps and make comparisons reproducible. It cannot claim a clinical trial, product test or laboratory result that never occurred.
Choose your next question
Connected reader paths
Women in research
A populated map of female and menopause relevance in the cited literature.
Read the guide
Peptide status
A dated FDA-linked classification and safety-concern snapshot.
Read the guide
COA field map
What each field can answer and what remains unknown.
Read the guide
Creatine specifications
A dated two-product specification comparison with linked certification records; not hands-on testing.
Read the guide
Testing policy
What must exist before “tested” can be claimed.
Read the guide
A clearer way through the topic
Define the decision
Separate the symptom, goal, product or measurement from the promise around it.
Match the evidence
Check population, route, outcome, study design and how directly the evidence applies.
Keep limits visible
Look for alternatives, contraindications, uncertainty, and the point where professional care matters.
How to use this hub
Use the source and date shown on each linked page, then read its method and limits. These are selected editorial resources, not a complete research database, live regulatory feed or clinical guideline. Unreported details must not be assumed.
Use the linked pages to prepare better questions. Educational material cannot diagnose, prescribe, or replace care from a qualified professional who knows your history.
Evidence boundaries
- Human outcomes are kept separate from mechanisms and animal research.
- Women- and life-stage-specific evidence is identified when available.
- Products, ingredients, routes and regulatory categories are not treated as interchangeable.
Authoritative starting points
Five public-source layers for a reader decision
| Layer | Authoritative starting point | Question it helps answer |
|---|---|---|
| Life-stage definition | STRAW+10 executive summary | How reproductive-aging stages are described; not a personal diagnosis |
| Symptom orientation | U.S. Office on Women’s Health | Common experiences and care orientation |
| Healthy-aging context | National Institute on Aging | Menopause, symptoms and broader midlife health |
| Treatment regulation | FDA menopause medicines | Approved-product framing and benefit–risk discussion |
| Evidence interpretation | TFB evidence method | Population, outcome, design, limits and applicability |
Inclusion method: public, stable, authoritative or peer-reviewed sources with a clear role in stage definition, symptom orientation, treatment regulation or evidence interpretation. Exclusions: seller pages, unsourced prevalence claims, non-reproducible rankings and inaccessible details. For a current treatment or regulatory question, open the linked primary source rather than relying on the date of this directory.
Background source
The NIH Office of Research on Women’s Health is a starting point for the broader research context. It did not produce, audit or endorse TFB’s linked editorial resources. The source-layer links above have their own specific roles.
- ORWH Home. Checked 2026-08-25.